Kaléo Pharmaceutical Inc.

An Ohio law allowing pharmacists to provide the opioid overdose reversal drug naloxone without a prescription led to a 2,328% increase in orders dispensed there, according to a study published in the

The US Food and Drug Administration is hoping a written statement, rather than a label change, will suffice as the necessary clarification that the injectable naloxone formulation is appropriate for c

Reviews of abbreviated new drug applications referencing opioid overdose treatments based on nalmefene or naloxone will now be expedited by the US Food and Drug Administration. Specifically, the agenc

The US Food and Drug Administration is willing to help sponsors resurrect extinct naloxone products in addition to expediting assessments of new ANDAs. In an 8 July announcement re-affirming the agenc